ID
38315
Description
Study ID: 103860/277 Clinical Study ID: 103860/277 Study Title: Phase III study of immunogenicity and safety of 3 doses of GSK Biologicals' thimerosal-free hepatitis B vaccine compared to the US-licensed GSK Biologicals' preservative-free hepatitis B vaccine when administered intramuscularly on a 0, 1, 6-month schedule to healthy infants in their first two weeks of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: BIO HBV; Engerix-B Study Indication: Hepatitis B
Keywords
Versions (2)
- 10/8/19 10/8/19 -
- 10/9/19 10/9/19 -
Copyright Holder
GlaxoSmithKline
Uploaded on
October 9, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Immunogenicity and safety of hepatitis B vaccine when administered intramuscularly to healthy infants in their first two weeks of life (103860/277)
Visit 2 - Pre-Vaccination Assessment
- StudyEvent: ODM
Description
Pre-Vaccination Assessment
Alias
- UMLS CUI-1
- C0042196
- UMLS CUI-2
- C0220825
- UMLS CUI-3
- C0332152
Description
Pre-Vaccination Temperature
Data type
float
Measurement units
- °F
Alias
- UMLS CUI [1,1]
- C0005903
- UMLS CUI [1,2]
- C0042196
- UMLS CUI [1,3]
- C0332152
Description
Temperature Route
Data type
integer
Alias
- UMLS CUI [1,1]
- C0005903
- UMLS CUI [1,2]
- C0449687
Similar models
Visit 2 - Pre-Vaccination Assessment
- StudyEvent: ODM
C0220825 (UMLS CUI-2)
C0332152 (UMLS CUI-3)
C0042196 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])
C0449687 (UMLS CUI [1,2])